Traverse Biotech is focused on developing innovative immunotherapy solutions, particularly targeting underserved medical conditions. The company is advancing a pipeline of differentiated immuno-oncology products derived from clinically validated therapeutic platforms. One of their key technologies is the CD3 X ROR2 DuoBody™, which aims to engage T cells in treating various oncology indications. ROR2 is identified as a promising target due to its involvement in tumor-dependent pathways that are reactivated during cancer development, making it a strategic focus for their therapeutic efforts.

In addition to their DuoBody™ platform, Traverse Biotech is also exploring oral innate immunotherapy stimulants that activate monocytic cells using pathogen-associated molecular patterns (PAMPs). This approach is supported by a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases. Furthermore, the company has entered into a licensing agreement with Genmab to develop a bispecific antibody targeting a tumor-associated antigen, which aims to enhance T cell-mediated cytotoxicity against both solid and liquid tumors. Through these technologies, Traverse Biotech is committed to accelerating the availability of effective immunotherapies for patients worldwide.

United States

Traverse Biotech develops innovative internationally sourced technologies from the pre-clinical stage through clinical proof-of-concept, driving significant value for shareholders and maximizing patient benefit. 

Traverse Biotech

Company Details